Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 88

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 88
---
 capital we believe is required for our operations in the short-term and may need to raise additional funds to complete such short-term operations. Such additional fundraises may not be available on terms acceptable to us, or at all.

55

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical or current facts included in this prospectus are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that “we believe” or similar statements reflect our beliefs and opinions on the relevant subject. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed in, or implied by these, forward-looking statements and therefore, you should not unduly rely on such statements, including, but not limited to:

| ● | expectations for increases or decreases in expenses; |

| ● | expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidates or any other products we may acquire or in-license; |

| ● | use of clinical research centers and other contractors; |

| ● | expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; |

| ● | expectations for generating revenue or becoming profitable on a sustained basis; |

| ● | expectations or ability to enter into marketing and other partnership agreements; |

| ● | expectations or ability to enter into product acquisition and in-licensing transactions; |

| ● | expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidates, if approved; |

| ● | expectations for the acceptance of our product candidates, if approved, by doctors, patients or payors; |

| ● | ability to compete against other companies and research institutions; |

| ● | our ability to attract, hire and retain qualified personnel, including the impact of our recently announced reduction in force;